Ishita Drugs

{
  "main_header": {
    "sid": 444125,
    "name": "Ishita Drugs",
    "stock_name": "Ishita Drugs",
    "full_name": "Ishita Drugs & Industries Ltd",
    "name_url": "stocks-analysis/ishita-drugs",
    "exchange": 0,
    "exchangecode": "",
    "primexch": 0,
    "country_id": 34,
    "currency": "INR",
    "cmp": "68.00",
    "chg": -3.9,
    "chgp": "-5.42%",
    "dir": -1,
    "prev_price": "71.90",
    "mcapval": "22.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 524400,
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE806D01016",
    "curr_date": "Mar 06",
    "curr_time": "",
    "bse_nse_vol": "53 ",
    "exc_status": "Active",
    "traded_date": "Mar 06, 2026",
    "traded_date_str": "2026 03 06",
    "score": "",
    "scoreText": "",
    "Live": 1,
    "market_time": 1,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/ishita-drugs-444125-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Are Ishita Drugs & Industries Ltd latest results good or bad?",
        "link": "https://www.marketsmojo.com/news/result-analysis/are-ishita-drugs-industries-ltd-latest-results-good-or-bad-3826846",
        "imagepath": "",
        "date": "2026-02-07 19:19:19",
        "description": "Ishita Drugs & Industries Ltd's latest financial results for Q2 FY26 reveal significant operational challenges. The company reported a net profit of ₹0.14 crores, which reflects a substantial decline compared to the previous quarter's ₹0.30 crores, indicating ongoing volatility in earnings. Revenue also saw a notable contraction, falling to ₹3.07 crores from ₹5.40 crores in Q1 FY26, marking a sharp decrease of 43.15% quarter-on-quarter. This decline in revenue is concerning as it highlights the company's struggle to maintain consistent sales growth, with year-on-year revenue also down by 6.12%.\n\nThe operating margin for the quarter was recorded at 6.19%, which is a slight decrease from the previous quarter's 6.48%. This suggests that while the company has managed to maintain some cost discipline, the overall profitability has been adversely affected by the significant drop in sales volume. Additionally, the..."
      },
      {
        "title": "Ishita Drugs Q2 FY26: Profit Slumps 26% as Revenue Volatility Persists",
        "link": "https://www.marketsmojo.com/news/result-analysis/ishita-drugs-q2-fy26-profit-slumps-26-as-revenue-volatility-persists-3826780",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/IshitaDrugsIndu_quaterlyResult_3826780.png",
        "date": "2026-02-07 17:46:41",
        "description": "Ishita Drugs & Industries Ltd., a micro-cap pharmaceutical manufacturer with a market capitalisation of ₹21.00 crores, reported disappointing results for Q2 FY26, with net profit declining 26.32% quarter-on-quarter to ₹0.14 crores from ₹0.30 crores in Q1 FY26. The sharp contraction in profitability came despite the company maintaining a relatively stable operating margin profile, raising concerns about the sustainability of earnings amidst persistent revenue volatility."
      },
      {
        "title": "Why is Ishita Drugs & Industries Ltd falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-ishita-drugs-industries-ltd-fallingrising-3792375",
        "imagepath": "",
        "date": "2026-01-15 00:43:51",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Intraday Price Movement and Market Sentiment</strong></p>\n<p>The stock opened with a gap up of 4.26%, signalling renewed buying interest early in the session. It further climbed to an intraday high of ₹75.95, marking a 9.98% surge from the previous close. This sharp rebound came after four consecutive days of decline, suggesting a short-term trend reversal. Notably, Ishita Drugs outperformed its sector by 5.98% on the day, indicating relative strength amid broader market pressures.</p>\n<p>Investor participation has also increased significantly, with delivery volumes on 13 Jan rising by 162.97% compared to the five-day average. This surge in volume points to heightened investor interest, potentially driven by the stock’s attractive valuation metrics and recent profit growth, despite its recen..."
      },
      {
        "title": "Ishita Drugs & Industries Ltd Downgraded to Strong Sell Amid Mixed Fundamentals and Technicals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/ishita-drugs-industries-ltd-downgraded-to-strong-sell-amid-mixed-fundamentals-and-technicals-3782570",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/IshitaDrugsIndu_mojoScore_3782570.png",
        "date": "2026-01-06 08:21:38",
        "description": "Ishita Drugs & Industries Ltd has seen its investment rating downgraded from Sell to Strong Sell as of 5 January 2026, reflecting a deterioration in technical indicators and persistent fundamental weaknesses. Despite a modest uptick in share price and some valuation appeal, the company’s financial trends and technical signals have raised concerns among analysts, prompting a reassessment of its outlook within the Pharmaceuticals & Biotechnology sector."
      },
      {
        "title": "Ishita Drugs & Industries Ltd Upgraded to Sell on Technical Improvements Despite Flat Financials",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/ishita-drugs-industries-ltd-upgraded-to-sell-on-technical-improvements-despite-flat-financials-3774372",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/IshitaDrugsIndu_mojoScore_3774372.png",
        "date": "2025-12-30 08:21:10",
        "description": "Ishita Drugs & Industries Ltd has seen its investment rating upgraded from Strong Sell to Sell as of 29 Dec 2025, driven primarily by a shift in technical indicators despite persistent fundamental weaknesses. The company’s Mojo Score rose to 34.0, reflecting a modest improvement in market sentiment, while its valuation and financial trends continue to pose challenges for investors."
      },
      {
        "title": "Ishita Drugs & Industries Ltd is Rated Strong Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/ishita-drugs-industries-ltd-is-rated-strong-sell-3770886",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/IshitaDrugsIndu_mojoScore_3770886.png",
        "date": "2025-12-26 15:13:38",
        "description": "Ishita Drugs & Industries Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 27 October 2025. However, the analysis and financial metrics discussed here reflect the company’s current position as of 26 December 2025, providing investors with the latest insights into its performance and outlook."
      },
      {
        "title": "Ishita Drugs Sees Revision in Market Assessment Amidst Challenging Fundamentals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/ishita-drugs-downgraded-to-strong-sell-amid-weak-fundamentals-and-bearish-technicals-3750585",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/IshitaDrugs_mojoScore_3750585.png",
        "date": "2025-12-08 10:10:34",
        "description": "Ishita Drugs, a microcap player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market evaluation reflecting recent shifts in its fundamental and technical outlook. This adjustment highlights ongoing challenges in the company’s financial and operational metrics, which investors should consider carefully."
      }
    ],
    "total": 107,
    "sid": "444125",
    "stock_news_url": "https://www.marketsmojo.com/news/ishita-drugs-industries-444125"
  },
  "announcements": [
    {
      "caption": "Disclosure Under Regulation 29(2) Of SEBI (Substantial Acquisition Of Shares & Takeovers) Regulations 2011",
      "datetime": "27-Feb-2026",
      "details": "Disclosure under regulation 29(2) of SEBI(SAST) Regulations 2011 received from Ishita Pharmaceuticals related party of Ishita Drgs and Industrie Limited.",
      "source": "BSE"
    },
    {
      "caption": "Disclosure Under Regulation 29(2) Of SEBI (Substantial Acquisition Of Shares & Takeovers) Regulations 2011",
      "datetime": "24-Feb-2026",
      "details": "Disclosure under regulation 29(2) of SEBI(SAST)Regulations 2011 received from Ishita Pharmaceuticals related party of Ishita Drugs and Industries Limited.",
      "source": "BSE"
    },
    {
      "caption": "Disclosure Under Regulation 29(2) Of SEBI (Substantial Acquisition Of Shares & Takeovers) Regulations 2011",
      "datetime": "19-Feb-2026",
      "details": "Disclosure under regulation 29(2) of SEBI (SAST) Regulations 2011 received from Ishita Pharmaceuticals related party of Ishita Drugs and Industries Limited.",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "No <strong>Dividend</strong> history available",
      "data": []
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Are Ishita Drugs & Industries Ltd latest results good or bad?

2026-02-07 19:19:19

Ishita Drugs & Industries Ltd's latest financial results for Q2 FY26 reveal significant operational challenges. The company reported a net profit of ₹0.14 crores, which reflects a substantial decline compared to the previous quarter's ₹0.30 crores, indicating ongoing volatility in earnings. Revenue also saw a notable contraction, falling to ₹3.07 crores from ₹5.40 crores in Q1 FY26, marking a sharp decrease of 43.15% quarter-on-quarter. This decline in revenue is concerning as it highlights the company's struggle to maintain consistent sales growth, with year-on-year revenue also down by 6.12%. The operating margin for the quarter was recorded at 6.19%, which is a slight decrease from the previous quarter's 6.48%. This suggests that while the company has managed to maintain some cost discipline, the overall profitability has been adversely affected by the significant drop in sales volume. Additionally, the...

Read full news article

Ishita Drugs Q2 FY26: Profit Slumps 26% as Revenue Volatility Persists

2026-02-07 17:46:41

Ishita Drugs & Industries Ltd., a micro-cap pharmaceutical manufacturer with a market capitalisation of ₹21.00 crores, reported disappointing results for Q2 FY26, with net profit declining 26.32% quarter-on-quarter to ₹0.14 crores from ₹0.30 crores in Q1 FY26. The sharp contraction in profitability came despite the company maintaining a relatively stable operating margin profile, raising concerns about the sustainability of earnings amidst persistent revenue volatility.

Read full news article

Why is Ishita Drugs & Industries Ltd falling/rising?

2026-01-15 00:43:51

Intraday Price Movement and Market Sentiment

The stock opened with a gap up of 4.26%, signalling renewed buying interest early in the session. It further climbed to an intraday high of ₹75.95, marking a 9.98% surge from the previous close. This sharp rebound came after four consecutive days of decline, suggesting a short-term trend reversal. Notably, Ishita Drugs outperformed its sector by 5.98% on the day, indicating relative strength amid broader market pressures.

Investor participation has also increased significantly, with delivery volumes on 13 Jan rising by 162.97% compared to the five-day average. This surge in volume points to heightened investor interest, potentially driven by the stock’s attractive valuation metrics and recent profit growth, despite its recen...

Read full news article

Ishita Drugs & Industries Ltd Downgraded to Strong Sell Amid Mixed Fundamentals and Technicals

2026-01-06 08:21:38

Ishita Drugs & Industries Ltd has seen its investment rating downgraded from Sell to Strong Sell as of 5 January 2026, reflecting a deterioration in technical indicators and persistent fundamental weaknesses. Despite a modest uptick in share price and some valuation appeal, the company’s financial trends and technical signals have raised concerns among analysts, prompting a reassessment of its outlook within the Pharmaceuticals & Biotechnology sector.

Read full news article

Ishita Drugs & Industries Ltd Upgraded to Sell on Technical Improvements Despite Flat Financials

2025-12-30 08:21:10

Ishita Drugs & Industries Ltd has seen its investment rating upgraded from Strong Sell to Sell as of 29 Dec 2025, driven primarily by a shift in technical indicators despite persistent fundamental weaknesses. The company’s Mojo Score rose to 34.0, reflecting a modest improvement in market sentiment, while its valuation and financial trends continue to pose challenges for investors.

Read full news article

Ishita Drugs & Industries Ltd is Rated Strong Sell

2025-12-26 15:13:38

Ishita Drugs & Industries Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 27 October 2025. However, the analysis and financial metrics discussed here reflect the company’s current position as of 26 December 2025, providing investors with the latest insights into its performance and outlook.

Read full news article

Ishita Drugs Sees Revision in Market Assessment Amidst Challenging Fundamentals

2025-12-08 10:10:34

Ishita Drugs, a microcap player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market evaluation reflecting recent shifts in its fundamental and technical outlook. This adjustment highlights ongoing challenges in the company’s financial and operational metrics, which investors should consider carefully.

Read full news article

View All News